Search results
ASCO: With hopes high, Regeneron misses mark with just 1 complete response in solid tumor trial so...
FierceBiotech· 12 hours agoRegeneron’s costimulatory bispecific antibody REGN7075 is being tested in patients with advanced...
Dynamic Technology Lab Private Ltd Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ETF DAILY NEWS· 1 day agoDynamic Technology Lab Private Ltd purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the fourth quarter, according to the company ...
Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 48% Discount?
Simply Wall St. via Yahoo Finance· 2 days agoKey Insights Regeneron Pharmaceuticals' estimated fair value is US$1,903 based on 2 Stage Free Cash...
Regeneron Files Second BPCIA Complaint Against Celltrion’s Proposed EYLEA® Biosimilar CT-P42 | JD...
JD Supra· 1 day agoOn May 17, 2024, Regeneron filed a second infringement litigation against Celltrion’s proposed EYLEA® (aflibercept) biosimilar CT-P42, Case No....
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 12 hours agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new results from an ongoing Phase 1/2 trial evaluating its first-in-class costimulatory bispecific ...
3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years
Motley Fool via Yahoo Finance· 23 hours agoNvidia (NASDAQ: NVDA), Netflix (NASDAQ: NFLX), and Regeneron Pharmaceuticals (NASDAQ: REGN) have...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron...
NBC 10 - FOX 14 Monroe· 2 days agoPomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors ...
Regeneron CEO Leonard Schleifer sells over $22 million in company stock By Investing.com
Investing.com· 6 days agoIn a recent transaction, Leonard S. Schleifer, the CEO and Co-Chair of Regeneron (NASDAQ:REGN)...
RBC maintains $1,185 target on Regeneron amid court case By Investing.com
Investing.com· 7 days agoOn Friday, RBC Capital maintained its Outperform rating on Regeneron (NASDAQ:REGN) Pharmaceuticals...
Regeneron faces new biosimilar threats; an AI biotech lays off staff
BioPharma Dive via Yahoo Finance· 2 days agoDrop us a line! Today, a brief rundown of news from Boehringer Ingelheim, as well as notes on GSK,...